Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Pacific Biosciences Of California, Inc. (PACB)
Price$1.32Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160.0M | $154.0M | $200.5M | $128.3M | $130.5M | $78.9M | $90.9M | $78.6M | $93.5M | $90.7M | $92.8M | $60.6M | $28.2M | $26.0M | $33.9M | $1.7M | $135,000 |
| Gross profit | $45.8M | $37.3M | $52.8M | $49.0M | $58.9M | $32.6M | $34.6M | $25.1M | $34.7M | $44.2M | $53.5M | $23.4M | $6.4M | $940,000 | $13.0M | $1.7M | $135,000 |
| Gross margin | 28.61% | 24.21% | 26.32% | 38.22% | 45.10% | 41.28% | 38.04% | 31.92% | 37.08% | 48.68% | 57.61% | 38.62% | 22.78% | 3.62% | 38.49% | 100.00% | 100.00% |
| Research & development | $97.3M | $134.9M | $187.2M | $193.0M | $112.9M | $64.2M | $59.6M | $62.6M | $65.3M | $67.6M | $60.4M | $48.2M | $45.2M | $47.6M | $76.1M | $111.8M | $75.9M |
| Operating expenses | $599.6M | $511.6M | $387.2M | $356.2M | $269.3M | $137.0M | $135.1M | $126.1M | $124.4M | $115.4M | $82.6M | $86.3M | $84.0M | $95.3M | $122.8M | $141.9M | $88.2M |
| Operating income | −$553.9M | −$474.3M | −$334.5M | −$307.2M | −$210.4M | −$104.4M | −$100.5M | −$101.0M | −$89.8M | −$71.2M | −$29.1M | −$62.9M | −$77.5M | −$94.3M | −$109.8M | — | — |
| Operating margin | −346.15% | −307.97% | −166.80% | −239.43% | −161.24% | −132.31% | −110.62% | −128.44% | −96.06% | −78.54% | −31.40% | −103.73% | −275.16% | −363.08% | −324.12% | — | — |
| EBITDA | −$171.4M | −$433.1M | −$314.7M | −$296.8M | −$202.8M | −$98.0M | −$93.3M | −$93.8M | −$81.3M | −$67.4M | −$25.5M | −$58.6M | −$71.9M | −$87.7M | −$104.0M | — | — |
| EBITDA margin | −107.14% | −281.23% | −156.96% | −231.33% | −155.41% | −124.16% | −102.63% | −119.26% | −87.03% | −74.27% | −27.44% | −96.76% | −255.12% | −337.49% | −306.98% | — | — |
| Net income | −$546.4M | −$309.9M | −$306.7M | −$314.2M | −$181.2M | $29.4M | −$84.1M | −$102.6M | −$92.2M | −$74.4M | −$31.7M | −$66.2M | −$79.3M | −$94.5M | −$109.4M | −$140.2M | −$87.7M |
| Net profit margin | −341.47% | −201.18% | −152.97% | −244.92% | −138.85% | 37.27% | −92.57% | −130.44% | −98.63% | −81.99% | −34.16% | −109.19% | −281.37% | −363.56% | −323.03% | −8,373.12% | −64,965.19% |
| Basic EPSper basic share | -$1.82 | -$1.13 | -$1.21 | -$1.40 | -$0.89 | $0.18 | -$0.55 | -$0.76 | -$0.87 | -$0.83 | -$0.42 | -$0.94 | -$1.26 | -$1.69 | -$2.03 | -$14.10 | -$173.03 |
| Diluted EPSper diluted share | -$1.82 | -$1.59 | -$1.21 | -$1.40 | -$0.89 | $0.17 | -$0.55 | -$0.76 | -$0.87 | -$0.83 | -$0.42 | -$0.94 | -$1.26 | -$1.69 | -$2.03 | -$14.10 | -$173.03 |
Owners
Reported shareholders
10.40%of listed shares
BlackRock, Inc.32.34M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.40%32.34M shares |
ARK Investment Management LLC | 9.58%29.78M shares |
SOFTBANK GROUP CORP. | 6.58%20.45M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.31%13.4M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.45%7.61M shares |
Sumitomo Mitsui Trust Group, Inc. | 1.93%6.01M shares |
Amova Asset Management Americas, Inc. | 1.93%6.01M shares |
STATE STREET CORP | 1.92%5.96M shares |
Point72 Asset Management, L.P. | 1.54%4.79M shares |
TWO SIGMA INVESTMENTS, LP | 1.37%4.24M shares |
D. E. Shaw & Co., Inc. | 1.35%4.21M shares |
MILLENNIUM MANAGEMENT LLC | 1.27%3.96M shares |
HENRY CHRISTIAN O | ≈1.15%3.58M shares |
GOLDMAN SACHS GROUP INC | 1.04%3.23M shares |
CITADEL ADVISORS LLC | 0.92%2.85M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.86%2.67M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.85%2.65M shares |
NORTHERN TRUST CORP | 0.76%2.35M shares |
Van Oene Mark | ≈0.72%2.24M shares |
VANGUARD FIDUCIARY TRUST CO | 0.70%2.19M shares |
Percentages use 310.81M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 1, 2026Form 4 | Gibson James R IISee Remarks | SellCommon Stock | 88.2K | $1.37 | $120.8K | 1.25M |
| Mar 3, 2026Form 4 | HENRY CHRISTIAN OSee Remarks | SellCommon Stock | 12.5K | $1.51 | $18.9K | 3.58M |
| Mar 3, 2026Form 4 | Van Oene MarkSee Remarks | SellCommon Stock | 6.5K | $1.51 | $9.8K | 2.24M |
| Mar 3, 2026Form 4 | Farmer MicheleSee Remarks | SellCommon Stock | 3.0K | $1.51 | $4.5K | 305.9K |
| Feb 18, 2026Form 4 | Van Oene MarkSee Remarks | SellCommon Stock | 55.1K | $1.63 | $89.8K | 1.74M |